Click on each modality below to learn more
Data driven multimodal assessment
of psychiatric and neurological health
Deliberate brings world-class expertise in behavioral and peripheral physiological biomarkers, feature selection, and multimodal biomarker fusion to the CNS community. Deliberate’s technology extracts hundreds of features from audio-visual signals and other modalities from which clinically significant Biomarker Constellations (multimodal computational biomarkers) and AI-COAs™ (clinically validated models that predict gold standard FDA approved Clinical Outcome Assessments) can be computed. Deliberate's Biomarker Discovery and Validation Platform, Multitude™, provides state-of-the-art AI and machine learning techniques to better understand, measure, and develop predictions for psychiatric and neurologic disorders.
The science is in
Biomarkers across a range of domains have been shown to correlate with virtually every CNS indication. But unlike the other therapeutic areas such as oncology, individual biomarkers often fail to achieve clinical relevance in CNS. New research, supported by recent advances in multimodal machine learning, is revealing that combinations of biomarkers - what we call Biomarker Constellations - can add unprecedented value for new drug and medical device development, and ultimately in clinical care.
Check it out
The Sankey diagram below is a visualization of a database of biomarker-CNS indication correlations that Deliberate’s data science and clinical teams have carefully curated and update regularly as new research comes to light. By hovering over or clicking on the various biomarker modalities and/or CNS indications, you will see the scientific evidence we have reviewed.
If you'd like to access hot links to the multitude of academic research driving this diagram (free with registration), click the button below.
A powerful new tool for CNS Biomarker Discovery and Development.
Deliberate offers the life sciences industry the first industrial-grade platform that extracts hundreds of behavioral and physiological features from ordinary video clips, which can be captured through Zoom, on a mobile phone or from in-person assessments. But it doesn't stop there. Multitude also facilitates feature selection, helping researchers to identify the features that are most closely correlated with disease processes of interest. Further, Multitude facilitates the fusion of different biomarker modalities, including those from outside our platform, and includes a variety of tools that will help data science teams to build high-performance models to discover, enrich and validate different kinds of biomarkers. With Multitude, the journey between raw data and useful models has gotten a lot shorter and smoother!
CURRENT INPUT MODALITY
CONTINUOUS PASSIVE SENSING
PARTNER OR FUTURE MODALITIES
FEATURE EXTRACTION TOOLKIT (FET)
OCULOMETRY & PUPILLOMETRY
DISCOVERY TOOLKIT (DTK)
BIOMARKER AND PHENOTYPE EVALUATION
CLASSICAL ML AND DEEP LEARNING
MODEL TRAINING AND EVALUATION
A multitude of use cases
Multitude™ can be used by CNS-focused biopharma and medical device companies to create high impact biomarker constellations from the first stages of clinical development through to clinical trial enhancement and real world evidence collection. Multitude is designed to support the discovery, development, and validation of most types of biomarkers: predictive, response , diagnostic, monitoring, and beyond. Following are a few use cases in which Multitude is gaining traction.
Use Case #1: Patient Identification, Stratification and Companion Diagnostics
Analyze subgroups of high and low responders to identify predictive biomarkers for successful disease classification and patient stratification. Leverage this information prospectively for subsequent phases for enhancing trial success and develop companion diagnostics.
Use Case #2: Endpoint Enhancement
Increase power and reduce trial sizes by 10-30% using current gold-standard primary endpoints for CNS clinical trials with “AI-COAs™ (AI-driven clinical outcome assessments). Discover and validate novel endpoints and biomarker constellations to quantify treatment response and strengthen evidence generation of drug efficacy.
Use Case #3: Increased Patient Safety and Trial De-risking
Identify prognostic and predictive biomarkers to risk-stratify patients and reduce the potential of adverse events in subsequent phases. Reduce non-adherence, dropout and negative trial outcomes to strengthen evidence for regulatory approval.
Use Case #4: Real-world Evidence
Generate real-world data, insights and evidence from clinical trial audio and video recordings on the optimal patient profile for treatment response and gain a comprehensive understanding of side effects unachievable by clinician monitoring alone. Generate evidence to support label extension.
Use Case #?: You Tell Us
Didn’t see the use case you were looking for? Have ideas for leveraging multimodal biomarker constellations in different ways? Let us know what you’re thinking!
Many ways to partner
Deliberate loves win-win partnerships.
Licensing - Deliberate licenses Multitude™ to biopharma and medical device companies interested in using the platform to pursue their own proprietary research and development. Ready to learn more? Contact us.
Co-development - We also love collaborating with partners on mutually beneficial research and development programs. Some projects are better pursued in partnership.
Birds of a Feather - While Deliberate is a leader in behavioral and physiological biomarkers, multimodal machine learning, and biomarker fusion, we recognize and value experts in other biomarker modalities such as retinal scanning, EEG, neuroimaging, genomics, proteomics, microbiome, and other. We firmly believe that when it comes to CNS biomarkers, there is a real need for trans-modality collaboration.